Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis
Donglin Ding(Mayo Clinic), Haojie Huang(Mayo Clinic)
Cited by 21
Related Papers
FOXO1 Inhibits Runx2 Transcriptional Activity and Prostate Cancer Cell Migration and Invasion
|Cancer Research|2011|163
BRCA1 is a negative modulator of the PRC2 complex
|The EMBO Journal|2013|114
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
|Nature Communications|2021|89
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
|Journal of Clinical Investigation|2021|87